Lito Souza, the 59-year-old pilot and digital creator behind Aviões e Músicas, has received the first dose of experimental drug ALN-6457 while in intensive care at Hospital Israelita Albert Einstein in São Paulo. His case has drawn attention both for the speed of the operation that brought the drug from Switzerland and for the uncertainty surrounding a treatment that has not undergone broad human testing.

Accounts focused on the family’s update stress his immediate condition rather than any claim of success. Souza’s wife, Mila Seidl, said he had no medication-related complications and was stable within the seriousness of his illness: “I do not have an outcome answer for you.” She said a meaningful comparison may take about six weeks, adding that the drug is not something that produces recovery immediately.¹

That caution is echoed in reporting on the drug’s scientific status. ALN-6457 uses RNA interference in an attempt to reduce production of the normal prion protein, PrP, whose abnormal form is linked to the brain damage caused by Creutzfeldt-Jakob disease. The intended effect is to slow the supply of material involved in the disease process, not to reverse neurological injury already sustained.²

Both accounts describe an exceptional logistical and regulatory effort. After arriving at Guarulhos airport, the medicine was cleared through an expedited process involving Brazil’s health regulator Anvisa and the Federal Revenue service, then flown by helicopter to the hospital. The authorization was granted on a compassionate-use basis for Souza’s individual case, rather than as approval of the drug for general use.²

For Seidl and Souza’s supporters, the dose represents a rare opportunity amid a fast-progressing, incurable disorder. For the scientific account, it is an unproven intervention: doctors cannot yet say whether it will slow the disease, nor fully define its side effects. The shared message is that the first administration marks the beginning of observation, not a confirmed breakthrough.